T1	Treatment 0 9	Denosumab
T2	Treatment 24 39	zoledronic acid
T3	Treatment 192 201	denosumab
T4	Treatment 302 322	with zoledronic acid
T5	Treatment 489 557	receive either subcutaneous denosumab 120 mg and intravenous placebo
T6	Treatment 570 664	or intravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo
T7	Treatment 739 766	daily calcium and vitamin D
T8	Treatment 925 942	RESULTS Denosumab
T9	Treatment 956 974	to zoledronic acid
T10	Treatment 1487 1501	with denosumab
T11	Treatment 1557 1567	denosumab;
T12	Treatment 1574 1590	zoledronic acid;
T13	Treatment 1601 1621	CONCLUSION Denosumab
T14	Treatment 1635 1653	to zoledronic acid
T15	Treatment 1859 1868	denosumab
